Nektar Therapeutics
NKTR
$56.90
-$2.02-3.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -122.27M | -133.04M | -118.96M | -168.30M | -177.08M |
| Total Depreciation and Amortization | 1.97M | 3.21M | 4.39M | 5.71M | 6.41M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.46M | -47.34M | -54.92M | -14.40M | -185.00K |
| Change in Net Operating Assets | -14.15M | 293.00K | -6.22M | 423.00K | -3.91M |
| Cash from Operations | -184.91M | -176.87M | -175.71M | -176.57M | -174.76M |
| Capital Expenditure | -1.16M | -1.31M | -1.47M | -1.25M | -613.00K |
| Sale of Property, Plant, and Equipment | 65.39M | 65.39M | 65.39M | 0.00 | 1.25M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 135.41M | 102.93M | 78.65M | 100.99M | 109.40M |
| Cash from Investing | 199.63M | 167.00M | 142.57M | 99.74M | 110.04M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 314.00K | 122.00K | 118.00K | 47.00K | 34.00K |
| Repurchase of Common Stock | -3.00M | -3.00M | -6.00M | -6.00M | -3.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.00M | 3.00M | 48.00M | 48.00M | 45.00M |
| Cash from Financing | 314.00K | 122.00K | 42.12M | 42.05M | 42.03M |
| Foreign Exchange rate Adjustments | 10.00K | 3.00K | -4.00K | -29.00K | -99.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 15.05M | -9.75M | 8.98M | -34.81M | -22.79M |